Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BERRY GLOBAL GROUP, INC.BERY · Entity 80192 | Director | November 25, 2023 | November 28, 2023 |
| Edwards Lifesciences CorpEW · Entity 3026 | CVP, Chief Financial Officer | May 11, 2026 | May 12, 2026 |
| ILLUMINA, INC.ILMN · Entity 3137 | Director | September 30, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BERRY GLOBAL GROUP, INC.
Report date November 25, 2023 · Filed November 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,728 |
Reported balance
After 2023-11-25 transaction · row 1
1 source rowRow 1 · 2023-11-25 · Exercise / conversion · Acquired 1,970 · Balance 4,728 F1: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,393 |
Reported balance
After 2023-11-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-11-25 · Exercise / conversion · Disposed 1,970 · Balance 1,393 F1: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F2: The award was granted on November 25, 2022 and vested in full on November 25, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
F2: The award was granted on November 25, 2022 and vested in full on November 25, 2023.
Edwards Lifesciences Corp
Report date May 11, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,740 |
Ending reported balance
After 2026-05-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-11 · Exercise / conversion · Acquired 19,830 · Balance 57,744 F1: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. Row 2 · 2026-05-11 · Tax withholding · Disposed 11,004 · Balance 46,740 |
| Performance RightsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-11 · Exercise / conversion · Disposed 19,830 · Balance 0 F1: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. F2: These Performance Rights expire on May 10, 2030. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 266,318 |
Reported balance
Holding disclosure · report date 2026-05-11 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 266,318 |
Filing footnotes · ownership attribution and instrument terms
F1: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4.
F2: These Performance Rights expire on May 10, 2030.
ILLUMINA, INC.
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,143 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 113 · Balance 11,143 F1: Mr. Ullem elected to receive 100% of his 2026 board and committee cash retainer fees in Illumina stock. The number of shares issued in lieu of cash is based on the quotient of (i) the cash compensation otherwise payable for the immediately completed quarter divided by (ii) the volume weighted average closing price per share during the immediately completed quarter, calculated by reference to each trading day during such quarter. The amount reported on this Form represents Mr. Ullem's 3rd quarter 2026 retainer fees. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Ullem elected to receive 100% of his 2026 board and committee cash retainer fees in Illumina stock. The number of shares issued in lieu of cash is based on the quotient of (i) the cash compensation otherwise payable for the immediately completed quarter divided by (ii) the volume weighted average closing price per share during the immediately completed quarter, calculated by reference to each trading day during such quarter. The amount reported on this Form represents Mr. Ullem's 3rd quarter 2026 retainer fees.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2025 Filed Feb 28, 2025 22:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,490 | $71.38 | $249,122.83 |
DisclosureSEC source: 0001225208-25-002619 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,147 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 19, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.23 to $71.69. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2025 Filed Feb 28, 2025 22:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 11,250 | $45.28 | $509,362.88 |
DisclosureSEC source: 0001225208-25-002619 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,637 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 19, 2024. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 174 | $76.19 | $13,257.06 |
DisclosureSEC source: 0001225208-25-001908 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,387 Read SEC document |
| February 13, 2025 Filed Feb 13, 2025 23:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 11,250 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-25-001712 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Stock · 11,250 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2025 Filed Feb 13, 2025 23:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 11,250 | $75.76 | $852,271.88 |
DisclosureSEC source: 0001225208-25-001712 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,561 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 19, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $75.1900 to $76.1201. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2025 Filed Feb 13, 2025 23:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 11,250 | $45.28 | $509,362.88 |
DisclosureSEC source: 0001225208-25-001712 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 19, 2024. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 01:28 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 158 | $142.06 | $22,446.10 |
DisclosureSEC source: 0001127602-25-000136 · form4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,891 F1 · shares: Mr. Ullem elected to receive 100% of his 2024 board and committee cash retainer fees in Illumina stock. The number of shares issued in lieu of cash is based on the quotient of (i) the cash compensation otherwise payable for the immediately completed quarter divided by (ii) the volume weighted average closing price per share during the immediately completed quarter, calculated by reference to each trading day during such quarter. The amount reported on this Form represents Mr. Ullem's 4th quarter 2024 retainer fees. Read SEC document |
| December 09, 2024 Filed Dec 9, 2024 21:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 11,250 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-24-010647 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 11,250 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2024 Filed Dec 9, 2024 21:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 11,250 | $71.68 | $806,405.63 |
DisclosureSEC source: 0001225208-24-010647 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,561 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 19, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.290 to $71.965. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 09, 2024 Filed Dec 9, 2024 21:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 11,250 | $45.28 | $509,362.88 |
DisclosureSEC source: 0001225208-24-010647 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 19, 2024. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 21:05 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 183 | $122.78 | $22,468.61 |
DisclosureSEC source: 0001127602-24-024722 · form4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,733 F1 · shares: Mr. Ullem elected to receive 100% of his 2024 board and committee cash retainer fees in Illumina stock. The number of shares issued in lieu of cash is based on the quotient of (i) the cash compensation otherwise payable for the immediately completed quarter divided by (ii) the volume weighted average closing price per share during the immediately completed quarter, calculated by reference to each trading day during such quarter. The amount reported on this Form represents Mr. Ullem's 3rd quarter 2024 retainer fees. Read SEC document |
| June 28, 2024 Filed Jul 1, 2024 20:13 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 205 | $109.65 | $22,479.03 |
DisclosureSEC source: 0001127602-24-019543 · form4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,550 F1 · shares: Mr. Ullem elected to receive 100% of his 2024 board and committee cash retainer fees in Illumina stock. The number of shares issued in lieu of cash is based on the quotient of (i) the cash compensation otherwise payable for the immediately completed quarter divided by (ii) the volume weighted average closing price per share during the immediately completed quarter, calculated by reference to each trading day during such quarter. The amount reported on this Form represents Mr. Ullem's 2nd quarter 2024 retainer fees. F2 · balance_after: In connection with Illumina's spin out of Grail, Inc., which was completed on June 24, 2024, all unvested equity award units were adjusted pursuant to Illumina's Amended and Restated 2015 Stock and Incentive Plan. Mr. Ullem's unvested RSUs were increased by 53 units as a result of such adjustment. Read SEC document |
| June 20, 2024 Filed Jun 20, 2024 21:43 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,625 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-24-006925 · doc4.xml · derivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 5,625 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2024 Filed Jun 20, 2024 21:43 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,225 | $87.47 | $457,012.99 |
DisclosureSEC source: 0001225208-24-006925 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,561 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $87.065 to $87.860. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 20, 2024 Filed Jun 20, 2024 21:43 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 400 | $88.11 | $35,245.00 |
DisclosureSEC source: 0001225208-24-006925 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,786 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $88.110 to $88.115. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 20, 2024 Filed Jun 20, 2024 21:43 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,625 | $45.28 | $254,681.44 |
DisclosureSEC source: 0001225208-24-006925 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2024. Read SEC document |
| May 21, 2024 Filed May 21, 2024 21:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,625 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-24-006287 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,875 Underlying: Common Stock · 5,625 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2024 Filed May 21, 2024 21:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,625 | $90.45 | $508,803.19 |
DisclosureSEC source: 0001225208-24-006287 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,561 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $90.225 to $90.720. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 21, 2024 Filed May 21, 2024 21:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,625 | $45.28 | $254,681.44 |
DisclosureSEC source: 0001225208-24-006287 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2024. Read SEC document |
| May 16, 2024 Filed May 17, 2024 22:03 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 2,622 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-015920 · form4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,292 F1 · shares: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| May 11, 2024 Filed May 13, 2024 21:45 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,198 | $86.72 | $103,890.56 |
DisclosureSEC source: 0001225208-24-005978 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,561 Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 11,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005885 · doc4.xml · derivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,075 Underlying: Common Stock · 11,075 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 65,500 | $0.00 Strike: $85.84 | $0.00 |
DisclosureSEC source: 0001225208-24-005885 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,500 Underlying: Common Stock · 65,500 shares Expires 2031-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 790 | $85.09 | $67,221.10 |
DisclosureSEC source: 0001225208-24-005885 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,759 Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 11,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005885 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,549 F1 · shares: These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 04, 2024 Filed May 6, 2024 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 7,465 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005707 · doc4.xml · derivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,465 shares Expires 2028-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 04, 2024 Filed May 6, 2024 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 4,431 | $85.25 | $377,742.75 |
DisclosureSEC source: 0001225208-24-005707 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,474 Read SEC document |
| May 04, 2024 Filed May 6, 2024 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,465 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005707 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 03, 2024 Filed May 6, 2024 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 634 | $85.06 | $53,928.04 |
DisclosureSEC source: 0001225208-24-005707 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,440 Read SEC document |
| April 30, 2024 Filed Apr 30, 2024 20:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,250 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-24-005397 · doc4.xml · derivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,250 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2024 Filed Apr 30, 2024 20:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,550 | $85.74 | $561,579.32 |
DisclosureSEC source: 0001225208-24-005397 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,074 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $85.350 to $86.350. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 30, 2024 Filed Apr 30, 2024 20:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 700 | $86.40 | $60,482.52 |
DisclosureSEC source: 0001225208-24-005397 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,624 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $86.375 to $86.470. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 30, 2024 Filed Apr 30, 2024 20:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,250 | $36.75 | $266,437.50 |
DisclosureSEC source: 0001225208-24-005397 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. Read SEC document |
| April 01, 2024 Filed Apr 1, 2024 22:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,255 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-24-004692 · doc4.xml · derivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,250 Underlying: Common Stock · 7,255 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2024 Filed Apr 1, 2024 22:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,387 | $94.81 | $605,520.81 |
DisclosureSEC source: 0001225208-24-004692 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,074 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $94.38 to $95.22. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 01, 2024 Filed Apr 1, 2024 22:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 868 | $95.51 | $82,902.68 |
DisclosureSEC source: 0001225208-24-004692 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,461 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. Read SEC document |
| April 01, 2024 Filed Apr 1, 2024 22:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,255 | $36.75 | $266,621.25 |
DisclosureSEC source: 0001225208-24-004692 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. Read SEC document |
| March 28, 2024 Filed Apr 2, 2024 21:09 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 163 | $137.68 | $22,442.17 |
DisclosureSEC source: 0001127602-24-011920 · form4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,670 F1 · shares: Mr. Ullem elected to receive 100% of his 2024 board and committee cash retainer fees in Illumina stock. The number of shares issued in lieu of cash is based on the quotient of (i) the cash compensation otherwise payable for the immediately completed quarter divided by (ii) the volume weighted average closing price per share during the immediately completed quarter, calculated by reference to each trading day during such quarter. The amount reported on this Form represents Mr. Ullem's 1st quarter 2024 retainer fees. Read SEC document |
| February 29, 2024 Filed Feb 29, 2024 22:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,255 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-24-003305 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,505 Underlying: Common Stock · 7,255 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2024 Filed Feb 29, 2024 22:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,255 | $85.59 | $620,922.80 |
DisclosureSEC source: 0001225208-24-003305 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,074 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $85.02 to $86.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 29, 2024 Filed Feb 29, 2024 22:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,255 | $36.75 | $266,621.25 |
DisclosureSEC source: 0001225208-24-003305 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. Read SEC document |
| February 16, 2024 Filed Feb 16, 2024 23:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 174 | $86.04 | $14,970.96 |
DisclosureSEC source: 0001225208-24-002345 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,074 Read SEC document |
| February 01, 2024 Filed Feb 1, 2024 22:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,255 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-24-001384 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,760 Underlying: Common Stock · 7,255 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2024 Filed Feb 1, 2024 22:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,255 | $78.29 | $567,993.95 |
DisclosureSEC source: 0001225208-24-001384 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,248 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. Read SEC document |
| February 01, 2024 Filed Feb 1, 2024 22:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,255 | $36.75 | $266,621.25 |
DisclosureSEC source: 0001225208-24-001384 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. Read SEC document |
| December 29, 2023 Filed Dec 29, 2023 21:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 14,510 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-23-011362 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,015 Underlying: Common Stock · 14,510 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 29, 2023 Filed Dec 29, 2023 21:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 14,510 | $76.55 | $1,110,794.19 |
DisclosureSEC source: 0001225208-23-011362 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,248 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $76.25 to $76.73. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 29, 2023 Filed Dec 29, 2023 21:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 14,510 | $36.75 | $533,242.50 |
DisclosureSEC source: 0001225208-23-011362 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023. Read SEC document |
| November 25, 2023 Filed Nov 28, 2023 21:32 UTC | BERRY GLOBAL GROUP, INC. BERY · Entity 80192 | Exercise / conversionRestricted Stock Units · Derivative | 1,970 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001378992-23-000124 · form4.xml · derivative · entry 2 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,393 Underlying: Common Stock · 1,970 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F2 · derivative.exercise_date: The award was granted on November 25, 2022 and vested in full on November 25, 2023. F2 · derivative.expiration_date: The award was granted on November 25, 2022 and vested in full on November 25, 2023. Read SEC document |
| November 25, 2023 Filed Nov 28, 2023 21:32 UTC | BERRY GLOBAL GROUP, INC. BERY · Entity 80192 | Exercise / conversionCommon Stock | 1,970 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001378992-23-000124 · form4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of BERY common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.